What's Happening?
The Critical Path Institute (C-Path) is set to host its 2026 Global Impact Conference (CGIC) in Washington, D.C., from September 15-16, with a special working session on September 17. The conference will take place at the Washington Marriott at Metro
Center and aims to address significant challenges in drug development, particularly focusing on how evidence of efficacy and safety is generated and interpreted. The event will bring together leaders from regulatory agencies, the pharmaceutical industry, academia, and advocacy groups, as well as individuals with lived experiences. Keynote speakers include Michael Davis, M.D., Ph.D., acting director of the FDA's Center for Drug Evaluation and Research, and Janet Woodcock, M.D., former principal deputy commissioner of the FDA. The conference will feature plenary panels, targeted workshops, and networking opportunities, all designed to foster collaboration and advance solutions in drug development.
Why It's Important?
The 2026 Global Impact Conference is crucial as it addresses the pressing need to transform the paradigm of evidence generation in drug development. This transformation is vital for ensuring that new treatments reach patients more efficiently and reliably. By convening a diverse group of stakeholders, including regulators, industry leaders, and patient advocates, the conference aims to foster collaboration and innovation in the field. The focus on modernizing evidence generation, including the use of artificial intelligence and real-world data, reflects the industry's shift towards more data-driven and patient-centered approaches. The outcomes of this conference could significantly impact how new therapies are developed, evaluated, and brought to market, ultimately benefiting patients and healthcare systems globally.
What's Next?
Following the conference, C-Path will continue its efforts to modernize drug development through its One to Millions initiative, which focuses on scaling individualized therapies. The initiative aims to improve how these therapies are developed, evaluated, and reimbursed. The conference's discussions and collaborations are expected to lead to actionable strategies and partnerships that will drive progress in the field. Stakeholders from various sectors, including regulatory bodies, pharmaceutical companies, and patient organizations, are likely to play a key role in implementing the insights and solutions generated at the conference.
